Technical Project Leader Novartis Pharma AG Basel, Basel-Stadt, Switzerland
By in large, oligonucleotide synthesis follows the extremely well-established and widely available solid phase phoshoramidite synthesis process, which serves as basis for virtually the entire portfolio of oligonucleotides that are in development and on the market. However, this process has certain limitations that require companies to develop clever scale-up strategies for registration and market entry, and to investigate alternative, innovative synthesis options. The presentation will shed light on the scale-up and manufacturing strategy to support a rapid launch, as well as on life-cycle management options to support predicted high volume market demands.
Understand strategies for scale-up of oligonucleotide drug supplies during development and market launch
Understand benefits and limitations of current manufacturing options to serve high market demands
Establish an outlook on use of innovative next-generation methodologies for oligonucleotides